Clinical Trial Update: Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating prasterone (dehydroepiandrosterone) for vaginal symptoms in postmenopausal cancer survivors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gynecologic Cancer

Drugs mentioned

• Prasterone (dehydroepiandrosterone (DHEA))

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Breast Cancer, Gynecologic Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-08-25